Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Income from Continuing Operations: 2022-2024

Historic Income from Continuing Operations for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to -$5.6 million.

  • Addex Therapeutics' Income from Continuing Operations rose 44.61% to -$892,300 in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.7 million, marking a year-over-year decrease of 9.28%. This contributed to the annual value of -$5.6 million for FY2024, which is 100.46% down from last year.
  • Addex Therapeutics' Income from Continuing Operations amounted to -$5.6 million in FY2024, which was down 100.46% from -$2.8 million recorded in FY2023.
  • Over the past 5 years, Addex Therapeutics' Income from Continuing Operations peaked at -$2.8 million during FY2023, and registered a low of -$11.3 million during FY2022.
  • In the last 3 years, Addex Therapeutics' Income from Continuing Operations had a median value of -$5.6 million in 2024 and averaged -$6.6 million.
  • Per our database at Business Quant, Addex Therapeutics' Income from Continuing Operations skyrocketed by 75.42% in 2023 and then plummeted by 100.46% in 2024.
  • Addex Therapeutics' Income from Continuing Operations (Yearly) stood at -$11.3 million in 2022, then soared by 75.42% to -$2.8 million in 2023, then slumped by 100.46% to -$5.6 million in 2024.